H.R. 8018: Increase Support for Life-saving Endocrine Transplantation Act

This bill, known as the Increase Support for Life-saving Endocrine Transplantation Act, aims to improve the regulation of human cadaveric islets for transplantation. Human cadaveric islets are clusters of cells in the pancreas that produce insulin, and their transplant can be a life-saving procedure for individuals with diabetes. The following key points summarize the main provisions of the bill:

Amendments to the Public Health Service Act

The bill proposes changes to Section 374(d)(2) of the Public Health Service Act. It specifically adds "human cadaveric islets" to the list of organs that can be regulated alongside the pancreas. This means that human cadaveric islets will be treated as organs for the purposes of regulation.

Clarifications on Definitions

The bill clarifies that several terms within the context of regulations do not include human cadaveric islets. These terms are:

• The term drug as defined in the Federal Food, Drug, and Cosmetic Act.
• The term biological product as defined in the Public Health Service Act.
• The term human cells, tissues, or cellular or tissue-based products (HCT/Ps) as defined in the relevant regulations.

This clarification indicates that human cadaveric islets will have distinct regulatory considerations and will not be categorized under these other definitions.

Updating Regulations

The bill mandates that within one year after its enactment, the Secretary of Health and Human Services must update the regulations concerning the transplantation of human cadaveric islets. These updates will be necessary to implement the changes made by the bill effectively.

Reporting Requirements

Additionally, the Secretary is required to report to Congress within six months following the enactment of the bill. This report should detail the progress made in updating the regulations related to human cadaveric islets.

Overall Impact

By introducing these changes, the bill aims to enhance the regulatory framework surrounding human cadaveric islet transplantation, potentially making the procedure more accessible and streamlined for patients in need.

Relevant Companies

None found